

19 July 2023

Company Announcements Office
Australian Securities Exchange

Appointment of Non-Executive Director

Nanosonics Limited (ASX: NAN) is pleased to announce the appointment of Dr Tracey Batten as a Non-executive Director of Nanosonics effective 26 September 2023.

Dr Batten brings to Nanosonics a wealth of experience in the healthcare sector gained in both non-executive and executive roles, as well as medical practitioner and clinical roles, over more than 30 years.

During her executive career, Dr Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles.

Dr Batten holds a Bachelor of Medicine/Bachelor of Surgery from the University of Melbourne, a Master of Health Administration from the University of New South Wales, and an MBA from Harvard Business School.

Dr Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited (NZX Listed), the Accident Compensation Corporation (a NZ Crown insurance scheme and investment fund) and the National Institute of Water and Atmospheric Research (a NZ Crown Research Institute). In addition, Dr Batten was previously non-executive director of Abano Healthcare Group Ltd (NZX Listed) and various other healthcare related research institutes, charities and industry and government bodies.

"On behalf of Nanosonics' shareholders and team, we are delighted to bring someone of Dr Batten's calibre and experience to the Nanosonics Board. We anticipate Tracey's international experience in healthcare as well as clinical practice will be invaluable in informing the Company's strategies for improving the way we serve our customers" said Steve Sargent, Nanosonics' Chairman.

"I am very pleased to be joining Nanosonics. The Company is at an exciting stage, and I look forward to working with my new colleagues on the Board and with management to continue to execute on Nanosonics' strategic growth agenda", said Dr Batten.

Authorised for release by the Board of Directors.